Deutsche Bank
UNCY icon

Deutsche Bank’s Unicycive Therapeutics UNCY Stock Holding History

Deutsche Bank’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$100K Sell
21,294
-2,980
-12% -$15.4K ﹤0.01% 3360
2026
Q2 		$114K Buy
+24,274
New +$179K ﹤0.01% 3447

Other funds holding UNCY

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Los Angeles Capital Management
Los Angeles Capital Management Los Angeles, California $29.2B AUM 33.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Deutsche Bank's UNCY Position: Q3 2026 in Review

Deutsche Bank reduced its Unicycive Therapeutics (UNCY) stake by 12% in Q3 2026, selling an estimated $15.4K and leaving 21,294 shares worth $100K. The position accounts for ﹤0.01% of the portfolio, ranked #3360.

Deutsche Bank first reported a position in UNCY in Q2 2026 and has held it in 2 quarters since. The position peaked at $114K in Q2 2026. 55 funds tracked by Wall St. Rank hold UNCY as of Q3 2026.

  • Deutsche Bank held 21,294 shares of Unicycive Therapeutics worth $100K as of Q3 2026.
  • Deutsche Bank sold 2,980 Unicycive Therapeutics shares in Q3 2026, an estimated $15.4K.
  • Unicycive Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3360 holding.
  • Deutsche Bank first reported a position in Unicycive Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Deutsche Bank's Unicycive Therapeutics position peaked at $114K in Q2 2026.
  • 55 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.